Form 4: Medpace CEO Sells Over 100K Shares in Pre-Planned Trades

Medpace Holdings, Inc. CEO August J. Troendle sold 101,417 shares of common stock for approximately $61.9 million in pre-arranged transactions.

Summary

• August J. Troendle, CEO, Director, and 10% Owner of Medpace Holdings, Inc. (MEDP), reported the sale of common stock.
• On November 24, 2025, 59,025 shares were sold at a weighted average price of $607.78 per share, with prices ranging from $593.46 to $617.165.
• On November 25, 2025, an additional 42,392 shares were sold at a weighted average price of $615.52 per share, with prices ranging from $610.50 to $626.545.
• The total number of shares sold across both transactions is 101,417.
• These transactions were executed pursuant to a pre-arranged Rule 10b5-1(c) plan.
• Following these sales, Mr. Troendle directly beneficially owns 732,210 shares of common stock.
• Mr. Troendle also indirectly beneficially owns 4,733,019 shares through Medpace Investors, LLC, where he is the sole manager and controlling unit holder.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to significant insider selling by the CEO. While the sales were pre-planned under a 10b5-1 plan, which mitigates some of the negative perception, a large disposition of shares by a key executive can still raise questions among investors about future growth prospects or valuation.

Positives

• The sales were conducted under a Rule 10b5-1(c) plan, indicating they were pre-planned and not based on immediate, non-public information, which can mitigate negative investor perception.

Negatives

• Significant insider selling by a CEO, Director, and 10% owner could be perceived negatively by investors, potentially signaling a desire to diversify holdings or a lack of confidence in the stock's near-term appreciation.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period.

Industry Context

Insider selling, even when pre-planned, is a common event in the market. For a company in the clinical research organization (CRO) sector like Medpace, such sales are typically viewed in the context of the company's overall financial performance and growth prospects. While not directly indicative of industry trends, significant insider sales can sometimes prompt closer scrutiny from investors regarding the company's valuation relative to its peers.

Related Party Transactions

• August J. Troendle indirectly beneficially owns 4,733,019 shares through Medpace Investors, LLC, where he serves as the sole manager and controlling unit holder. He disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders may interpret the significant insider selling as a signal regarding the executive's confidence in the company's future, potentially leading to increased scrutiny of the stock's performance.
• Employees, customers, suppliers, and creditors are unlikely to be directly impacted by this specific insider transaction report.

Key Dates

Recommendation

While the significant insider selling by the CEO could be a cause for concern, the fact that these transactions were executed under a pre-arranged Rule 10b5-1(c) plan suggests they are part of a personal financial strategy rather than a reaction to adverse company-specific news. Investors should monitor future insider activity and company performance, but this filing alone does not warrant a 'sell' recommendation, nor does it provide new positive catalysts for a 'buy'.

Keywords

Medpace Holdings, MEDP, August J. Troendle, Insider Selling, Form 4, Stock Sale, CEO, Director, 10b5-1 Plan, Beneficial Ownership